- Home
- ATLX vs UNCY Comparison
ATLX vs UNCY Comparison
Compare ATLX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATLX | UNCY |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Brazil | United States |
| Employees | 64 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 145.3M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATLX | UNCY |
|---|---|---|
| Price | $4.22 | $7.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 1.0M | 657.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $92,491.00 | ★ $675,000.00 |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.60 | $0.47 |
| 52 Week High | $8.25 | $8.74 |
Technical Indicators
Market Signals| Indicator | ATLX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 45.44 |
| Support Level | $3.97 | $7.05 |
| Resistance Level | $5.12 | $7.78 |
| Average True Range (ATR) | 0.35 | 0.51 |
| MACD | -0.10 | -0.15 |
| Stochastic Oscillator | 6.91 | 21.62 |
Price Performance
Historical ComparisonAbout ATLX Atlas Lithium Corporation
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.